Showing results (61-70 of 100) with videos related to
Sort By:
Pageof 10
Journal of Cancer|April 30, 2019
Nimotuzumab Plus Paclitaxel and Cisplatin as a 1st-Line Treatment for Esophageal Cancer: Long Term Follow-up of a Phase II StudyXiaodong Zhang, Jun Jia, Ming Lu, et al.Cancer Medicine|April 21, 2023
Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I studyDan Liu, Furong Kou, Jifang Gong, et al.Journal for Immunotherapy of Cancer|November 11, 2020
Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatmentZhenghang Wang, Xiaochen Zhao, Chan Gao, et al.Journal for Immunotherapy of Cancer|August 15, 2020
Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancerZhihao Lu, Huan Chen, Shuang Li, et al.Nature Communications|August 18, 2022
Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironmentYang Chen, Keren Jia, Yu Sun, et al.British Journal of Cancer|June 23, 2026
Efficacy and safety of infigratinib in patients with refractory advanced gastric or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification: a single-arm, multicenter phase 2 trialJiajia Yuan, Jifang Gong, Zhi Peng, et al.Frontiers in Pharmacology|August 8, 2022
A Phase Ib Study of the Simmitecan Single Agent and in Combination With 5-Fluorouracil/Leucovorin or Thalidomide in Patients With Advanced Solid TumorQi Zhang, Ting Deng, Fen Yang, et al.Eclinicalmedicine|January 18, 2024
Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trialYakun Wang, Jifang Gong, Airong Wang, et al.Nature Communications|May 11, 2026
The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib/II trialPanpan Zhang, Zuoxing Niu, Hongqian Guo, et al.NPJ Precision Oncology|May 5, 2021
A genomic mutation signature predicts the clinical outcomes of immunotherapy and characterizes immunophenotypes in gastrointestinal cancerXi Jiao, Xin Wei, Shuang Li, et al.Pageof 10